CLCS (Cell Source) 3-Year Revenue Growth Rate: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLCS Cell Source Inc CLCS
35 GF Score
Price $0.52
View Full Analysis

What is Cell Source 3-Year Revenue Growth Rate?

Cell Source CLCS -29.81% 35 3-Year Revenue Growth Rate is 0.00% as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Cell Source's Revenue per Share for the three months ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Cell Source  (OTCPK:CLCS) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Cell Source 3-Year Revenue Growth Rate Related Terms

CLCS vs EDSA, CTXR, ASBP: 3-Year Revenue Growth Rate Comparison

For the Biotechnology subindustry, Cell Source's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source 3-Year Revenue Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cell Source's 3-Year Revenue Growth Rate falls into.


CLCS
35GF Score
Cell Source Inc CLCS
3-Year Revenue Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

What does a 3-Year Revenue Growth Rate of 0.00% mean?
Cell Source (CLCS) has a 3-Year Revenue Growth Rate of 0.00% as of Dec. 2024. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Cell Source and its competitors.
Is Cell Source's 3-Year Revenue Growth Rate too high?
Cell Source's current 3-Year Revenue Growth Rate is 0.00%. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's 3-Year Revenue Growth Rate compare to EDSA and CTXR?
Cell Source's 3-Year Revenue Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. The industry median 3-Year Revenue Growth Rate is 3.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.10, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Cell Source and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current 3-Year Revenue Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current 3-Year Revenue Growth Rate of 0.00%. The current 3-Year Revenue Growth Rate is 0.00%. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Cell Source (CLCS), the current 3-Year Revenue Growth Rate is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price